ID NEU2_HUMAN Reviewed; 164 AA. AC P01185; A0AV35; O14935; DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot. DT 01-AUG-1992, sequence version 2. DT 13-FEB-2019, entry version 200. DE RecName: Full=Vasopressin-neurophysin 2-copeptin; DE AltName: Full=AVP-NPII; DE Contains: DE RecName: Full=Arg-vasopressin; DE AltName: Full=Arginine-vasopressin; DE Contains: DE RecName: Full=Neurophysin 2; DE AltName: Full=Neurophysin-II; DE Contains: DE RecName: Full=Copeptin; DE Flags: Precursor; GN Name=AVP; Synonyms=ARVP, VP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; OC Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; OC Catarrhini; Hominidae; Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=2991279; RA Sausville E., Carney D., Battey J.; RT "The human vasopressin gene is linked to the oxytocin gene and is RT selectively expressed in a cultured lung cancer cell line."; RL J. Biol. Chem. 260:10236-10241(1985). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=3768139; RA Rehbein M., Hillers M., Mohr E., Ivell R., Morley S., Schmale H., RA Richter D.; RT "The neurohypophyseal hormones vasopressin and oxytocin. Precursor RT structure, synthesis and regulation."; RL Biol. Chem. Hoppe-Seyler 367:695-704(1986). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=4065330; DOI=10.1016/0014-5793(85)80069-7; RA Mohr E., Hillers M., Ivell R., Haulica I.D., Richter D.; RT "Expression of the vasopressin and oxytocin genes in human RT hypothalami."; RL FEBS Lett. 193:12-16(1985). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT NDI VAL-48. RX PubMed=1740104; RA Bahnsen U., Oosting P., Swaab D.F., Nahke P., Richter D., Schmale H.; RT "A missense mutation in the vasopressin-neurophysin precursor gene RT cosegregates with human autosomal dominant neurohypophyseal diabetes RT insipidus."; RL EMBO J. 11:19-23(1992). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-119. RC TISSUE=Lung carcinoma; RA Du J., North W.G.; RT "A missense mutation in the vasopressin mRNA with human small-cell RT lung carcinoma."; RL Submitted (OCT-1997) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., RA Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., RA Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P., RA Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M., RA Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R., RA Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M., RA Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., RA Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., RA Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E., RA Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., RA Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M., RA Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A., RA Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., RA Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA RT project: the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP PROTEIN SEQUENCE OF 20-28, AND AMIDATION AT GLY-28. RX PubMed=13591312; RA Light A., du Vigneaud V.; RT "On the nature of oxytocin and vasopressin from human pituitary."; RL Proc. Soc. Exp. Biol. Med. 98:692-696(1958). RN [9] RP PROTEIN SEQUENCE OF 32-124. RX PubMed=6574452; DOI=10.1073/pnas.80.10.2839; RA Chauvet M.-T., Hurpet D., Chauvet J., Acher R.; RT "Identification of human neurophysins: complete amino acid sequences RT of MSEL- and VLDV-neurophysins."; RL Proc. Natl. Acad. Sci. U.S.A. 80:2839-2843(1983). RN [10] RP PROTEIN SEQUENCE OF 126-164. RX PubMed=7271787; DOI=10.1016/S0006-291X(81)80258-6; RA Seidah N.G., Benjannet S., Chretien M.; RT "The complete sequence of a novel human pituitary glycopeptide RT homologous to pig posterior pituitary glycopeptide."; RL Biochem. Biophys. Res. Commun. 100:901-907(1981). RN [11] RP VARIANT NDI THR-19. RX PubMed=8370682; DOI=10.1210/jcem.77.3.8370682; RA McLeod J.F., Kovacs L., Gaskill M.B., Rittig S., Bradley G.S., RA Robertson G.L.; RT "Familial neurohypophyseal diabetes insipidus associated with a signal RT peptide mutation."; RL J. Clin. Endocrinol. Metab. 77:599A-599G(1993). RN [12] RP VARIANT NDI GLU-78 DEL. RX PubMed=8103767; DOI=10.1210/jcem.77.3.8103767; RA Yuasa H., Ito M., Nagasaki H., Oiso Y., Miyamoto S., Sasaki N., RA Saito H.; RT "Glu-47, which forms a salt bridge between neurophysin-II and arginine RT vasopressin, is deleted in patients with familial central diabetes RT insipidus."; RL J. Clin. Endocrinol. Metab. 77:600-604(1993). RN [13] RP VARIANT NDI THR-19. RX PubMed=8514868; DOI=10.1172/JCI116494; RA Ito M., Oiso Y., Murase T., Kondo K., Saito H., Chinzei T., Racchi M., RA Lively M.O.; RT "Possible involvement of inefficient cleavage of preprovasopressin by RT signal peptidase as a cause for familial central diabetes insipidus."; RL J. Clin. Invest. 91:2565-2571(1993). RN [14] RP VARIANT NDI LEU-55. RX PubMed=8045958; DOI=10.1210/jcem.79.2.8045958; RA Repaske D.R., Browning J.E.; RT "A de novo mutation in the coding sequence for neurophysin-II RT (Pro24-->Leu) is associated with onset and transmission of autosomal RT dominant neurohypophyseal diabetes insipidus."; RL J. Clin. Endocrinol. Metab. 79:421-427(1994). RN [15] RP VARIANT NDI TRP-93. RX PubMed=7714110; DOI=10.1210/jcem.80.4.7714110; RA Nagasaki H., Ito M., Yuasa H., Saito H., Fukase M., Hamada K., RA Ishikawa E., Katakami H., Oiso Y.; RT "Two novel mutations in the coding region for neurophysin-II RT associated with familial central diabetes insipidus."; RL J. Clin. Endocrinol. Metab. 80:1352-1356(1995). RN [16] RP VARIANTS NDI PHE-17; THR-19; VAL-19; ARG-45; CYS-51; GLY-78; PRO-81; RP ARG-88; SER-88; SER-92 AND CYS-96. RX PubMed=8554046; RA Rittig S., Robertson G.L., Siggaard C., Kovacs L., Gregersen N., RA Nyborg J., Pedersen E.B.; RT "Identification of 13 new mutations in the vasopressin-neurophysin II RT gene in 17 kindreds with familial autosomal dominant neurohypophyseal RT diabetes insipidus."; RL Am. J. Hum. Genet. 58:107-117(1996). RN [17] RP VARIANT NDI VAL-54. RX PubMed=9360520; DOI=10.1210/jcem.82.11.4231; RA Gagliardi P.C., Bernasconi S., Repaske D.R.; RT "Autosomal dominant neurohypophyseal diabetes insipidus associated RT with a missense mutation encoding Gly23-->Val in neurophysin II."; RL J. Clin. Endocrinol. Metab. 82:3643-3646(1997). RN [18] RP VARIANT NDI THR-19. RX PubMed=9580132; DOI=10.1210/jcem.83.3.4658; RA Calvo B., Bilbao J.R., Urrutia I., Eizaguirre J., Gaztambide S., RA Castano L.; RT "Identification of a novel nonsense mutation and a missense RT substitution in the vasopressin-neurophysin II gene in two Spanish RT kindreds with familial neurohypophyseal diabetes insipidus."; RL J. Clin. Endocrinol. Metab. 83:995-997(1998). RN [19] RP VARIANTS NDI PHE-87 AND TYR-92. RX PubMed=9814475; DOI=10.1210/jcem.83.11.5278; RA Grant F.D., Ahmadi A., Hosley C.M., Majzoub J.A.; RT "Two novel mutations of the vasopressin gene associated with familial RT diabetes insipidus and identification of an asymptomatic carrier RT infant."; RL J. Clin. Endocrinol. Metab. 83:3958-3964(1998). RN [20] RP VARIANT NDI LEU-26. RX PubMed=10369876; DOI=10.1093/hmg/8.7.1303; RA Willcutts M.D., Felner E., White P.C.; RT "Autosomal recessive familial neurohypophyseal diabetes insipidus with RT continued secretion of mutant weakly active vasopressin."; RL Hum. Mol. Genet. 8:1303-1307(1999). RN [21] RP VARIANT NDI ARG-54. RX PubMed=10487710; DOI=10.1210/jcem.84.9.5979; RA Calvo B., Bilbao J.R., Rodriguez A., Rodriguez-Arnao M.D., Castano L.; RT "Molecular analysis in familial neurohypophyseal diabetes insipidus: RT early diagnosis of an asymptomatic carrier."; RL J. Clin. Endocrinol. Metab. 84:3351-3354(1999). RN [22] RP VARIANTS NDI ARG-116 AND GLY-116. RX PubMed=11017955; RA Abbes A.P., Bruggeman B., van den Akker E.L.T., de Groot M.R., RA Franken A.A.M., Drexhage V.R., Engel H.; RT "Identification of two distinct mutations at the same nucleotide RT position, concomitantly with a novel polymorphism in the vasopressin- RT neurophysin II gene (AVP-NP II) in two Dutch families with familial RT neurohypophyseal diabetes insipidus."; RL Clin. Chem. 46:1699-1702(2000). RN [23] RP VARIANT NDI TYR-59. RX PubMed=11150885; DOI=10.1159/000023573; RA Skordis N., Patsalis P.C., Hettinger J.A., Kontou M., Herakleous E., RA Krishnamani M.R., Phillips J.A. III; RT "A novel arginine vasopressin-neurophysin II mutation causes autosomal RT dominant neurohypophyseal diabetes insipidus and morphologic pituitary RT changes."; RL Horm. Res. 53:239-245(2000). RN [24] RP VARIANT NDI TYR-105. RX PubMed=10677561; RA Fujii H., Iida S., Moriwaki K.; RT "Familial neurohypophyseal diabetes insipidus associated with a novel RT mutation in the vasopressin-neurophysin II gene."; RL Int. J. Mol. Med. 5:229-234(2000). RN [25] RP VARIANT NDI PRO-97. RX PubMed=11748489; DOI=10.1055/s-2001-18994; RA Mundschenk J., Rittig S., Siggaard C., Hensen J., Lehnert H.; RT "A new mutation of the arginine vasopressin-neurophysin II gene in a RT family with autosomal dominant neurohypophyseal diabetes insipidus."; RL Exp. Clin. Endocrinol. Diabetes 109:406-409(2001). RN [26] RP VARIANT NDI GLY-116, AND CHARACTERIZATION OF VARIANT NDI GLY-116. RX PubMed=11443218; DOI=10.1210/jcem.86.7.7686; RA Nijenhuis M., van den Akker E.L.T., Zalm R., Franken A.A.M., RA Abbes A.P., Engel H., de Wied D., Burbach J.P.H.; RT "Familial neurohypophysial diabetes insipidus in a large Dutch RT kindred: effect of the onset of diabetes on growth in children and RT cell biological defects of the mutant vasopressin prohormone."; RL J. Clin. Endocrinol. Metab. 86:3410-3420(2001). RN [27] RP VARIANT NDI GLY-98. RX PubMed=11161827; DOI=10.1006/mgme.2000.3117; RA DiMeglio L.A., Gagliardi P.C., Browning J.E., Quigley C.A., RA Repaske D.R.; RT "A missense mutation encoding cys(67) --> gly in neurophysin ii is RT associated with early onset autosomal dominant neurohypophyseal RT diabetes insipidus."; RL Mol. Genet. Metab. 72:39-44(2001). RN [28] RP VARIANTS NDI ARG-54; TYR-92 AND ARG-105. RX PubMed=11980620; DOI=10.1530/eje.0.1460649; RA Rutishauser J., Kopp P., Gaskill M.B., Kotlar T.J., Robertson G.L.; RT "Clinical and molecular analysis of three families with autosomal RT dominant neurohypophyseal diabetes insipidus associated with a novel RT and recurrent mutations in the vasopressin-neurophysin II gene."; RL Eur. J. Endocrinol. 146:649-656(2002). RN [29] RP VARIANT NDI SER-92. RX PubMed=12012274; DOI=10.1055/s-2002-29091; RA Bullmann C., Kotzka J., Grimm T., Heppner C., Jockenhovel F., RA Krone W., Muller-Wieland D.; RT "Identification of a novel mutation in the arginine vasopressin- RT neurophysin II gene in familial central diabetes insipidus."; RL Exp. Clin. Endocrinol. Diabetes 110:134-137(2002). RN [30] RP VARIANT NDI HIS-21. RX PubMed=12107248; DOI=10.1210/jcem.87.7.8677; RA Rittig S., Siggaard C., Ozata M., Yetkin I., Gregersen N., RA Pedersen E.B., Robertson G.L.; RT "Autosomal dominant neurohypophyseal diabetes insipidus due to RT substitution of histidine for tyrosine-2 in the vasopressin moiety of RT the hormone precursor."; RL J. Clin. Endocrinol. Metab. 87:3351-3355(2002). RN [31] RP VARIANT NDI PHE-104. RX PubMed=12359138; DOI=10.1016/S1096-7192(02)00118-X; RA Santiprabhob J., Browning J.E., Repaske D.R.; RT "A missense mutation encoding Cys73Phe in neurophysin II is associated RT with autosomal dominant neurohypophyseal diabetes insipidus."; RL Mol. Genet. Metab. 77:112-118(2002). RN [32] RP VARIANT NDI THR-19. RX PubMed=12519420; DOI=10.1046/j.1365-2265.2003.01667.x; RA Boson W.L., Sarubi J.C., D'Alva C.B., Friedman E., Faria D., RA De Marco L., Wajchenberg B.; RT "A signal peptide mutation of the arginine vasopressin gene in RT monozygotic twins."; RL Clin. Endocrinol. (Oxf.) 58:108-110(2003). RN [33] RP VARIANT NDI PRO-99. RX PubMed=14510916; DOI=10.1046/j.1365-2265.2003.01834.x; RA Elias P.C.L., Elias L.L.K., Torres N., Moreira A.C., RA Antunes-Rodrigues J., Castro M.; RT "Progressive decline of vasopressin secretion in familial autosomal RT dominant neurohypophyseal diabetes insipidus presenting a novel RT mutation in the vasopressin-neurophysin II gene."; RL Clin. Endocrinol. (Oxf.) 59:511-518(2003). RN [34] RP VARIANT NDI PHE-58. RX PubMed=12931042; DOI=10.1159/000072526; RA Wolf M.T.F., Doetsch J., Metzler M., Holder M., Repp R., Rascher W.; RT "A new missense mutation of the vasopressin-neurophysin II gene in a RT family with neurohypophyseal diabetes insipidus."; RL Horm. Res. 60:143-147(2003). RN [35] RP VARIANT NDI SER-98. RX PubMed=15538939; DOI=10.1530/eje.0.1510605; RA Baglioni S., Corona G., Maggi M., Serio M., Peri A.; RT "Identification of a novel mutation in the arginine vasopressin- RT neurophysin II gene affecting the sixth intrachain disulfide bridge of RT the neurophysin II moiety."; RL Eur. J. Endocrinol. 151:605-611(2004). RN [36] RP VARIANTS NDI THR-19; VAL-19; ARG-54; ALA-67; GLY-78; GLU-78 DEL; RP ASP-96; CYS-96; GLY-104 AND TRP-116. RX PubMed=14673472; DOI=10.1038/sj.ejhg.5201086; RA Christensen J.H., Siggaard C., Corydon T.J., deSanctis L., Kovacs L., RA Robertson G.L., Gregersen N., Rittig S.; RT "Six novel mutations in the arginine vasopressin gene in 15 kindreds RT with autosomal dominant familial neurohypophyseal diabetes insipidus RT give further insight into the pathogenesis."; RL Eur. J. Hum. Genet. 12:44-51(2004). RN [37] RP FUNCTION OF VASOPRESSIN, MUTAGENESIS OF GLY-28, AND SUBUNIT. RX PubMed=18174156; DOI=10.1074/jbc.M706477200; RA Dutertre S., Croker D., Daly N.L., Andersson A., Muttenthaler M., RA Lumsden N.G., Craik D.J., Alewood P.F., Guillon G., Lewis R.J.; RT "Conopressin-T from Conus tulipa reveals an antagonist switch in RT vasopressin-like peptides."; RL J. Biol. Chem. 283:7100-7108(2008). CC -!- FUNCTION: Neurophysin 2 specifically binds vasopressin. CC -!- FUNCTION: Vasopressin has a direct antidiuretic action on the CC kidney, it also causes vasoconstriction of the peripheral vessels. CC Acts by binding to vasopressin receptors (V1bR/AVPR1B, CC V1aR/AVPR1A, and V2R/AVPR2) (PubMed:18174156). CC {ECO:0000269|PubMed:18174156}. CC -!- SUBUNIT: Interacts with vasopressin receptors V1bR/AVPR1B (Ki=85 CC pM), V1aR/AVPR1A (Ki=0.6 nM) and V2R/AVPR2 (Ki=4.9 nM) CC (PubMed:18174156). Interacts with oxytocin receptor (OXTR) (Ki=110 CC nM) (PubMed:18174156). {ECO:0000269|PubMed:18174156}. CC -!- SUBCELLULAR LOCATION: Secreted. CC -!- DISEASE: Diabetes insipidus, neurohypophyseal (NDI) [MIM:125700]: CC A disease characterized by persistent thirst, polydipsia and CC polyuria. Affected individuals are apparently normal at birth, but CC characteristically develop symptoms of vasopressin deficiency CC during childhood. {ECO:0000269|PubMed:10369876, CC ECO:0000269|PubMed:10487710, ECO:0000269|PubMed:10677561, CC ECO:0000269|PubMed:11017955, ECO:0000269|PubMed:11150885, CC ECO:0000269|PubMed:11161827, ECO:0000269|PubMed:11443218, CC ECO:0000269|PubMed:11748489, ECO:0000269|PubMed:11980620, CC ECO:0000269|PubMed:12012274, ECO:0000269|PubMed:12107248, CC ECO:0000269|PubMed:12359138, ECO:0000269|PubMed:12519420, CC ECO:0000269|PubMed:12931042, ECO:0000269|PubMed:14510916, CC ECO:0000269|PubMed:14673472, ECO:0000269|PubMed:15538939, CC ECO:0000269|PubMed:1740104, ECO:0000269|PubMed:7714110, CC ECO:0000269|PubMed:8045958, ECO:0000269|PubMed:8103767, CC ECO:0000269|PubMed:8370682, ECO:0000269|PubMed:8514868, CC ECO:0000269|PubMed:8554046, ECO:0000269|PubMed:9360520, CC ECO:0000269|PubMed:9580132, ECO:0000269|PubMed:9814475}. Note=The CC disease is caused by mutations affecting the gene represented in CC this entry. CC -!- SIMILARITY: Belongs to the vasopressin/oxytocin family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Wikipedia; Note=Vasopressin entry; CC URL="https://en.wikipedia.org/wiki/Vasopressin"; CC ----------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC ----------------------------------------------------------------------- DR EMBL; M11166; AAA98772.1; -; Genomic_DNA. DR EMBL; M25647; AAA61291.1; -; mRNA. DR EMBL; X03172; CAA26935.1; -; mRNA. DR EMBL; X62890; CAA44681.1; -; Genomic_DNA. DR EMBL; AF031476; AAB86629.1; -; mRNA. DR EMBL; AL160414; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; X62891; CAA44682.1; -; Genomic_DNA. DR EMBL; BC126196; AAI26197.1; -; mRNA. DR EMBL; BC126224; AAI26225.1; -; mRNA. DR CCDS; CCDS13045.1; -. DR PIR; A39269; A39269. DR PIR; B94676; NVHU2. DR RefSeq; NP_000481.2; NM_000490.4. DR RefSeq; XP_011527569.1; XM_011529267.1. DR UniGene; Hs.89648; -. DR ProteinModelPortal; P01185; -. DR SMR; P01185; -. DR BioGrid; 107032; 25. DR IntAct; P01185; 2. DR STRING; 9606.ENSP00000369647; -. DR iPTMnet; P01185; -. DR PhosphoSitePlus; P01185; -. DR BioMuta; AVP; -. DR DMDM; 128083; -. DR PaxDb; P01185; -. DR PeptideAtlas; P01185; -. DR PRIDE; P01185; -. DR ProteomicsDB; 51342; -. DR Ensembl; ENST00000380293; ENSP00000369647; ENSG00000101200. DR GeneID; 551; -. DR KEGG; hsa:551; -. DR CTD; 551; -. DR DisGeNET; 551; -. DR EuPathDB; HostDB:ENSG00000101200.5; -. DR GeneCards; AVP; -. DR HGNC; HGNC:894; AVP. DR HPA; CAB025318; -. DR HPA; HPA071892; -. DR MalaCards; AVP; -. DR MIM; 125700; phenotype. DR MIM; 192340; gene. DR neXtProt; NX_P01185; -. DR OpenTargets; ENSG00000101200; -. DR Orphanet; 30925; Hereditary central diabetes insipidus. DR PharmGKB; PA25186; -. DR eggNOG; ENOG410IXM5; Eukaryota. DR eggNOG; ENOG4111S8B; LUCA. DR GeneTree; ENSGT00390000004511; -. DR HOGENOM; HOG000113768; -. DR HOVERGEN; HBG004462; -. DR InParanoid; P01185; -. DR KO; K05242; -. DR OMA; GLCCNSE; -. DR OrthoDB; 1548839at2759; -. DR PhylomeDB; P01185; -. DR TreeFam; TF333018; -. DR Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression. DR Reactome; R-HSA-388479; Vasopressin-like receptors. DR Reactome; R-HSA-416476; G alpha (q) signalling events. DR Reactome; R-HSA-418555; G alpha (s) signalling events. DR Reactome; R-HSA-432040; Vasopressin regulates renal water homeostasis via Aquaporins. DR Reactome; R-HSA-5619099; Defective AVP does not bind AVPR1A,B and causes neurohypophyseal diabetes insipidus (NDI). DR Reactome; R-HSA-879518; Transport of organic anions. DR Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis. DR Reactome; R-HSA-8856828; Clathrin-mediated endocytosis. DR Reactome; R-HSA-9036092; Defective AVP does not bind AVPR2 and causes neurohypophyseal diabetes insipidus (NDI). DR SIGNOR; P01185; -. DR GeneWiki; Vasopressin; -. DR GenomeRNAi; 551; -. DR PMAP-CutDB; P01185; -. DR PRO; PR:P01185; -. DR Proteomes; UP000005640; Chromosome 20. DR Bgee; ENSG00000101200; Expressed in 67 organ(s), highest expression level in hypothalamus. DR Genevisible; P01185; HS. DR GO; GO:0030665; C:clathrin-coated vesicle membrane; TAS:Reactome. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030425; C:dendrite; IEA:Ensembl. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0005615; C:extracellular space; IEA:Ensembl. DR GO; GO:0030141; C:secretory granule; IEA:Ensembl. DR GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IDA:UniProtKB. DR GO; GO:0005185; F:neurohypophyseal hormone activity; IEA:InterPro. DR GO; GO:0005184; F:neuropeptide hormone activity; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0005102; F:signaling receptor binding; TAS:ProtInc. DR GO; GO:0031894; F:V1A vasopressin receptor binding; IPI:UniProtKB. DR GO; GO:0031895; F:V1B vasopressin receptor binding; IEA:Ensembl. DR GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc. DR GO; GO:0070371; P:ERK1 and ERK2 cascade; IDA:UniProtKB. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome. DR GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc. DR GO; GO:0007625; P:grooming behavior; IEA:Ensembl. DR GO; GO:0042538; P:hyperosmotic salinity response; IEA:Ensembl. DR GO; GO:0007626; P:locomotory behavior; IEA:Ensembl. DR GO; GO:0002125; P:maternal aggressive behavior; IEA:Ensembl. DR GO; GO:0042711; P:maternal behavior; IEA:Ensembl. DR GO; GO:0061024; P:membrane organization; TAS:Reactome. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB. DR GO; GO:0007621; P:negative regulation of female receptivity; IEA:Ensembl. DR GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; IDA:UniProtKB. DR GO; GO:0051970; P:negative regulation of transmission of nerve impulse; IEA:Ensembl. DR GO; GO:0043084; P:penile erection; IEA:Ensembl. DR GO; GO:0030307; P:positive regulation of cell growth; IEA:Ensembl. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0032849; P:positive regulation of cellular pH reduction; IEA:Ensembl. DR GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB. DR GO; GO:0014049; P:positive regulation of glutamate secretion; IEA:Ensembl. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0031394; P:positive regulation of prostaglandin biosynthetic process; IEA:Ensembl. DR GO; GO:0003084; P:positive regulation of systemic arterial blood pressure; IEA:Ensembl. DR GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:Ensembl. DR GO; GO:0070528; P:protein kinase C signaling; IDA:UniProtKB. DR GO; GO:0035813; P:regulation of renal sodium excretion; IEA:Ensembl. DR GO; GO:0003091; P:renal water homeostasis; TAS:Reactome. DR GO; GO:0045471; P:response to ethanol; IEA:Ensembl. DR GO; GO:0035094; P:response to nicotine; IEA:Ensembl. DR GO; GO:0033574; P:response to testosterone; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0035176; P:social behavior; IEA:Ensembl. DR GO; GO:0042310; P:vasoconstriction; IEA:UniProtKB-KW. DR GO; GO:0006833; P:water transport; TAS:ProtInc. DR Gene3D; 2.60.9.10; -; 1. DR InterPro; IPR000981; Neurhyp_horm. DR InterPro; IPR036387; Neurhyp_horm_dom_sf. DR InterPro; IPR022423; Neurohypophysial_hormone_CS. DR PANTHER; PTHR11681; PTHR11681; 1. DR Pfam; PF00220; Hormone_4; 1. DR Pfam; PF00184; Hormone_5; 1. DR PIRSF; PIRSF001815; Nonapeptide_hormone_precursor; 1. DR PRINTS; PR00831; NEUROPHYSIN. DR ProDom; PD001676; Neurhyp_horm; 1. DR SMART; SM00003; NH; 1. DR SUPFAM; SSF49606; SSF49606; 1. DR PROSITE; PS00264; NEUROHYPOPHYS_HORM; 1. PE 1: Evidence at protein level; KW Amidation; Cleavage on pair of basic residues; Complete proteome; KW Diabetes insipidus; Direct protein sequencing; Disease mutation; KW Disulfide bond; Glycoprotein; Hormone; Polymorphism; KW Reference proteome; Secreted; Signal; Vasoactive; Vasoconstrictor. FT SIGNAL 1 19 {ECO:0000269|PubMed:13591312}. FT PEPTIDE 20 28 Arg-vasopressin. FT {ECO:0000269|PubMed:13591312}. FT /FTId=PRO_0000020515. FT CHAIN 32 124 Neurophysin 2. FT {ECO:0000269|PubMed:6574452}. FT /FTId=PRO_0000020516. FT PEPTIDE 126 164 Copeptin. {ECO:0000269|PubMed:7271787}. FT /FTId=PRO_0000020517. FT SITE 28 28 Important for agonist activity on FT V1aR/AVPR1A. FT {ECO:0000269|PubMed:18174156}. FT MOD_RES 28 28 Glycine amide. FT {ECO:0000269|PubMed:13591312}. FT CARBOHYD 131 131 N-linked (GlcNAc...) asparagine. FT DISULFID 20 25 FT DISULFID 41 85 {ECO:0000250|UniProtKB:P01175}. FT DISULFID 44 58 {ECO:0000250|UniProtKB:P01175}. FT DISULFID 52 75 {ECO:0000250|UniProtKB:P01175}. FT DISULFID 59 65 {ECO:0000250|UniProtKB:P01175}. FT DISULFID 92 104 {ECO:0000250|UniProtKB:P01175}. FT DISULFID 98 116 {ECO:0000250|UniProtKB:P01175}. FT DISULFID 105 110 {ECO:0000250|UniProtKB:P01175}. FT VARIANT 17 17 S -> F (in NDI). FT {ECO:0000269|PubMed:8554046}. FT /FTId=VAR_004980. FT VARIANT 19 19 A -> T (in NDI; probably causes FT insufficient processing of precursor; FT dbSNP:rs387906511). FT {ECO:0000269|PubMed:12519420, FT ECO:0000269|PubMed:14673472, FT ECO:0000269|PubMed:8370682, FT ECO:0000269|PubMed:8514868, FT ECO:0000269|PubMed:8554046, FT ECO:0000269|PubMed:9580132}. FT /FTId=VAR_004981. FT VARIANT 19 19 A -> V (in NDI; dbSNP:rs387906512). FT {ECO:0000269|PubMed:14673472, FT ECO:0000269|PubMed:8554046}. FT /FTId=VAR_004982. FT VARIANT 21 21 Y -> H (in NDI; dbSNP:rs121964893). FT {ECO:0000269|PubMed:12107248}. FT /FTId=VAR_015262. FT VARIANT 26 26 P -> L (in NDI; weakly active; FT dbSNP:rs142886338). FT {ECO:0000269|PubMed:10369876}. FT /FTId=VAR_015263. FT VARIANT 45 45 G -> R (in NDI). FT {ECO:0000269|PubMed:8554046}. FT /FTId=VAR_004983. FT VARIANT 48 48 G -> V (in NDI; dbSNP:rs121964883). FT {ECO:0000269|PubMed:1740104}. FT /FTId=VAR_004984. FT VARIANT 51 51 R -> C (in NDI). FT {ECO:0000269|PubMed:8554046}. FT /FTId=VAR_004985. FT VARIANT 52 52 C -> R (in NDI). FT /FTId=VAR_015264. FT VARIANT 54 54 G -> R (in NDI; dbSNP:rs121964888). FT {ECO:0000269|PubMed:10487710, FT ECO:0000269|PubMed:11980620, FT ECO:0000269|PubMed:14673472}. FT /FTId=VAR_015265. FT VARIANT 54 54 G -> V (in NDI; dbSNP:rs121964887). FT {ECO:0000269|PubMed:9360520}. FT /FTId=VAR_015266. FT VARIANT 55 55 P -> L (in NDI). FT {ECO:0000269|PubMed:8045958}. FT /FTId=VAR_004986. FT VARIANT 58 58 C -> F (in NDI). FT {ECO:0000269|PubMed:12931042}. FT /FTId=VAR_029997. FT VARIANT 59 59 C -> R (in NDI). FT /FTId=VAR_015267. FT VARIANT 59 59 C -> Y (in NDI). FT {ECO:0000269|PubMed:11150885}. FT /FTId=VAR_015268. FT VARIANT 67 67 V -> A (in NDI; dbSNP:rs28934878). FT {ECO:0000269|PubMed:14673472}. FT /FTId=VAR_019273. FT VARIANT 78 78 E -> G (in NDI). FT {ECO:0000269|PubMed:14673472, FT ECO:0000269|PubMed:8554046}. FT /FTId=VAR_004988. FT VARIANT 78 78 Missing (in NDI). FT {ECO:0000269|PubMed:14673472, FT ECO:0000269|PubMed:8103767}. FT /FTId=VAR_004987. FT VARIANT 81 81 L -> P (in NDI). FT {ECO:0000269|PubMed:8554046}. FT /FTId=VAR_004989. FT VARIANT 82 82 P -> L (in dbSNP:rs5195). FT /FTId=VAR_011894. FT VARIANT 87 87 S -> F (in NDI; dbSNP:rs121964890). FT {ECO:0000269|PubMed:9814475}. FT /FTId=VAR_015269. FT VARIANT 88 88 G -> R (in NDI). FT {ECO:0000269|PubMed:8554046}. FT /FTId=VAR_004990. FT VARIANT 88 88 G -> S (in NDI; dbSNP:rs121964882). FT {ECO:0000269|PubMed:8554046}. FT /FTId=VAR_004991. FT VARIANT 92 92 C -> S (in NDI). FT {ECO:0000269|PubMed:12012274, FT ECO:0000269|PubMed:8554046}. FT /FTId=VAR_004992. FT VARIANT 92 92 C -> Y (in NDI; dbSNP:rs121964891). FT {ECO:0000269|PubMed:11980620, FT ECO:0000269|PubMed:9814475}. FT /FTId=VAR_015270. FT VARIANT 93 93 G -> W (in NDI; dbSNP:rs121964885). FT {ECO:0000269|PubMed:7714110}. FT /FTId=VAR_004993. FT VARIANT 96 96 G -> C (in NDI). FT {ECO:0000269|PubMed:14673472, FT ECO:0000269|PubMed:8554046}. FT /FTId=VAR_004994. FT VARIANT 96 96 G -> D (in NDI). FT {ECO:0000269|PubMed:14673472}. FT /FTId=VAR_019274. FT VARIANT 96 96 G -> V (in NDI; dbSNP:rs121964886). FT /FTId=VAR_015271. FT VARIANT 97 97 R -> C (in NDI). FT /FTId=VAR_015272. FT VARIANT 97 97 R -> P (in NDI). FT {ECO:0000269|PubMed:11748489}. FT /FTId=VAR_015273. FT VARIANT 98 98 C -> G (in NDI). FT {ECO:0000269|PubMed:11161827}. FT /FTId=VAR_015274. FT VARIANT 98 98 C -> S (in NDI). FT {ECO:0000269|PubMed:15538939}. FT /FTId=VAR_029998. FT VARIANT 99 99 A -> P (in NDI). FT {ECO:0000269|PubMed:14510916}. FT /FTId=VAR_029999. FT VARIANT 104 104 C -> F (in NDI). FT {ECO:0000269|PubMed:12359138}. FT /FTId=VAR_015275. FT VARIANT 104 104 C -> G (in NDI). FT {ECO:0000269|PubMed:14673472}. FT /FTId=VAR_019275. FT VARIANT 105 105 C -> R (in NDI). FT {ECO:0000269|PubMed:11980620}. FT /FTId=VAR_015276. FT VARIANT 105 105 C -> Y (in NDI). FT {ECO:0000269|PubMed:10677561}. FT /FTId=VAR_015279. FT VARIANT 116 116 C -> G (in NDI; strong accumulation in FT the endoplasmic reticulum and an altered FT morphology of this organelle; FT dbSNP:rs74315383). FT {ECO:0000269|PubMed:11017955, FT ECO:0000269|PubMed:11443218}. FT /FTId=VAR_015277. FT VARIANT 116 116 C -> R (in NDI). FT {ECO:0000269|PubMed:11017955}. FT /FTId=VAR_015278. FT VARIANT 116 116 C -> W (in NDI). FT {ECO:0000269|PubMed:14673472}. FT /FTId=VAR_019276. FT VARIANT 119 119 G -> V (in dbSNP:rs1051744). FT {ECO:0000269|Ref.5}. FT /FTId=VAR_011895. FT MUTAGEN 28 28 G->V: Gain of antagonist activity on FT V1aR/AVPR1A (and loss of agonist activity FT on this receptor). 42-fold decrease in FT affinity for V1aR/AVPR1A, 2000-fold FT decrease in affinity for V1bR/AVPR1B, 5- FT fold decrease in affinity for V2R/AVPR2 FT and no change in affinity for oxytocin FT receptor (OXTR). FT {ECO:0000269|PubMed:18174156}. FT CONFLICT 11 11 L -> P (in Ref. 1; AAA98772). FT {ECO:0000305}. FT CONFLICT 48 48 G -> D (in Ref. 5; AAB86629). FT {ECO:0000305}. SQ SEQUENCE 164 AA; 17325 MW; 8F5EF9834700B9AE CRC64; MPDTMLPACF LGLLAFSSAC YFQNCPRGGK RAMSDLELRQ CLPCGPGGKG RCFGPSICCA DELGCFVGTA EALRCQEENY LPSPCQSGQK ACGSGGRCAA FGVCCNDESC VTEPECREGF HRRARASDRS NATQLDGPAG ALLLRLVQLA GAPEPFEPAQ PDAY //